Fluoroquinolones and tuberculosis

Expert Opinion on Investigational Drugs

Volumn 11, Issue 2, 2002, Pages 233-258

  Bryskier, André ^a   Lowther, John ^a  

^a SANOFI   (France)

Author keywords

Anti TB drug; Ciprofloxacin; Fluoroquinolones; Levofloxacin; Ofloxacin; Sparfloxacin

Indexed keywords

1 CYCLOPROPYL 7 (2,6 DIMETHYL 4 PYRIDYL) 6 FLUORO 1,4 DIHYDRO 4 OXO 3 QUINOLINECARBOXYLIC ACID; 1 ETHYL 7 [3 (ETHYLAMINOMETHYL) 1 PYRROLIDINYL] 6,8 DIFLUORO 1,4 DIHYDRO 4 OXO 3 QUINOLINECARBOXYLIC ACID; 7 (2 AMINOMETHYL 4 MORPHOLINYL) 1 CYCLOPROPYL 6,8 DIFLUORO 1,4 DIHYDRO 4 OXO 3 QUINOLINECARBOXYLIC ACID; AMIFLOXACIN; CIPROFLOXACIN; CLINAFLOXACIN; DIFLOXACIN; ENOXACIN; ETHAMBUTOL; FLEROXACIN; GATIFLOXACIN; GREPAFLOXACIN; IRLOXACIN; ISONIAZID; LEVOFLOXACIN; LOMEFLOXACIN; MOXIFLOXACIN; NORFLOXACIN; OFLOXACIN; PEFLOXACIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SITAFLOXACIN; SPARFLOXACIN; STREPTOMYCIN; TEMAFLOXACIN; TROVAFLOXACIN; TUBERCULOSTATIC AGENT; UNINDEXED DRUG; ANTIINFECTIVE AGENT; DIAGNOSTIC AGENT; QUINOLONE DERIVATIVE;

ABORTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTHROPATHY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; DRUG STRUCTURE; DRUG TOLERANCE; EYE TOXICITY; HEPATITIS; HUMAN; IN VITRO STUDY; LIVER TOXICITY; LONG TERM CARE; MINIMUM INHIBITORY CONCENTRATION; MORBIDITY; MOUSE; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION; TUBERCULOSIS; VESTIBULAR DISORDER; ANIMAL; CHEMISTRY; CLINICAL TRIAL; DISEASE MODEL; DRUG COMBINATION; DRUG EFFECT; GENETICS; LUNG TUBERCULOSIS;

ANIMALS; ANTI-INFECTIVE AGENTS; ANTITUBERCULAR AGENTS; CLINICAL TRIALS; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; FLUOROQUINOLONES; HUMANS; MICE; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 0036170342     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.11.2.233     Document Type: Review

References (178)

1. Antituberculosis activity of ofloxacin (DL-8280) on experimental tuberculosis in mice
2. In vitro susceptibility of mycobacteria to ciprofloxacin
3. In vitro activity of ciprofloxacin against mycobacteria
4. New drugs for tuberculosis
5. Ciprofloxacin susceptibility testing by MIC and disk elution of drug-resistant Mycobacterium tuberculosis and Mycobacterium avium complex
6. Activity of ciprofloxacin against Mycobacterium in vitro: Comparaison of BACTEC and macrobroth dilution methods
7. Etest for susceptibility testing of Mycobacterium tuberculosis and Mycobacterium avium-intracellulare
8. Rapid assessment of drug susceptibility of M. tuberculosis by means of luciferase reporter phages
9. A rapid method for activity against a strain of M.tuberculosis expressing firefly luciferase
10. In vitro activity of six fluorinated quinolones against Mycobacterium tuberculosis
11. In vitro activities of quinolones against mycobacteria
12. In vitro activity of the new quinolones, with special reference to Mycobacterium, Nocardia and Rhodococcus
13. Activity of ciprofloxacin and other fluorinated quinolones against mycobacteria
14. Activities of pefloxacin and ofloxacin against mycobacteria: In vitro and mouse experiments
15. In vitro activity of fluoroquinolones against eighty-six isolates of mycobacteria
16. Etude de la sensibilité de sept espèces de mycobactéries aux nouvelles quinolones
17. In vitro and in vivo activity of sparfloxacin (AT 4140) against Mycobacterium tuberculosis
18. In vitro activity of the new quinolone lomefloxacin against Mycobacterium tuberculosis
19. Comparative in vitro activities of ciprofloxacin and other 4-quinolones against Mycobacterium tuberculosis and Mycobacterium intracellulare
20. In vitro activity of lomefloxacin against pathogenic and environmental mycobacteria
21. Comparative in vitro and in vivo activity of fleroxacin and ofloxacin against various mycobacteria
22. In vitro activity of the new difluorinated quinolone sparfloxacin (AT-4140) against Mycobacterium tuberculosis compared with activities of ofloxacin and ciprofloxacin
23. In vitro antituberculosis activity of a new antibacterial substance ofloxacin (DL 8280)
24. In vitro activity of norfloxacin and ciprofloxacin against Mycobacterium tuberculosis, M.avium complex, M.chelonei, M.fortuitum and M.kansasii
25. Comparative in vitro activities of ten fluoroquinolones and fusidic acid against Mycobacterium spp
26. Comparative in vitro activity of fleroxacin and other 6-fluoroquinolones against mycobacteria
27. Preliminary study of the in vitro activity of irloxacin against mycobacteria
28. s of WIN 57273 against Mycobacterium avium and Mycobacterium tuberculosis
29. In vitro activity of PD 127,391, an enhanced-spectrum quinolone
30. Comparative antimycobacterial activity of the newly synthesized quinolone, AM-1155, sparfloxacin and ofloxacin
31. Comparative in vitro activity of BAY y 3118 a new quinolone, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex
32. In vitro activity of five quinolones against cultivable mycobacteria
33. In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis
34. Inhibitory and bactericidal activities of levofloxacin against Mycobacterium tuberculosis in vitro and in human macrophages
35. Comparative in vitro activity of five fluoroquinolones against mycobacteria
36. Comparative in vitro activity of fluoroquinolones against Mycobacterium tuberculosis
37. In vitro activity of ciprofloxacin in combination with standard antituberculous drugs against Mycobacterium tuberculosis
38. Antimycobacterial activity of a newly synthesized fluoroquinolone, Y 26,611
39. In vitro and in vivo antimycobacterial activities of a new quinolone, DU-6859a
40. In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis
41. In vitro activity of BAY 12-8039, a new fluoroquinolone
42. In vitro activity of four fluoroquinolones against Mycobacterium tuberculosis
43. Comparative antimycobacterial activities of difloxacin, termafloxacin, enoxacin, pefloxacin, reference fluoroquinolones and a new macrolide, clarithromycin
44. Comparative in vitro antimicrobial activities of the newly synthetized quinolones HSR-903, sitafloxacin (DU 685a), gatifloxacin (AM-1155) and levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex
45. In vitro antibacterial spectrum of a new 8-methoxyfluoroquinolone, gatifloxacin
46. The in vitro activity of the novel des-fluoro (6) quinolone BMS-284,756 against anaerobes, Mycoplasma, Ureaplasma, Chlamydia and Mycobacterium spp
47. In vitro activity of fluorinated quinolones and macrolides against drug-resistant Mycobacterium tuberculosis
48. In vitro and in vivo activities of T-3811 ME, a novel des-F(6) quinolone
49. In vitro activities of six fluoroquinolones against 250 clinical isolates of Mycobacterium tuberculosis susceptible or resistant to first-line antituberculosis drugs
50. Activity of quinolones against mycobacteria
51. Comparative antimycobacterial activity of ofloxacin, ciprofloxacin and grepafloxacin
52. In vitro antimycobacterial activity of the new quinolone OPC-17116
53. In vitro activity of quinolones and macrolides against mycobacteria
54. Determination of antimycobacterial activities of fluoroquinolones against clinical isolates of Mycobacterium tuberculosis: Comparative determination with egg-based ogawa and agar-based Middlebrook 7H10 media
55. In vitro antimycobacterial activity of a new quinolone, NM 934
56. Comparative in vitro antimicrobial activity of the newly synthesized quinolones WQ-3034 and HSR-903 and other quinolones against Mycobacterium tuberculosis and Mycobacterium avium complex
57. Comparative antibacterial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex
58. In vitro activities of levofloxacin used alone, and in combination with first and second line antituberculous drugs against Mycobacterium tuberculosis
59. Détermination in vitro de la sensibilité des mycobactéries aux fluoroquinolones
60. Bacteriostatic and bactericidal activity of ciprofloxacin and ofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex
61. Therapeutic effect of a new antibacterial substance ofloxacin (DL 8280) on pulmonary tuberculosis
62. A controlled study of rifabutin and an uncontrolled study of ofloxacin in the retreatment of patients with pulmonary tuberculosis resistance to isoniazid, streptomycin and rifampicin
63. Emergence of fluoroquinolone resistant tuberculosis in New York City
64. Present aspects of bacterial resistance in tuberculosis
65. Molecular cloning of gyr A and gyr B genes of Mycobacterium tuberculosis: Analysis of nucleotide sequence
66. Differential of phylogenetically related slowly growing mycobacteria by their gyr B sequences
67. Differentiation of clinical Mycobacterium tuberculosis complex isolates by gyr B DNA sequence polymorphism analysis
68. Correlation between quinolone susceptibility patterns and sequences in the A and B subunits of DNA gyrase in mycobacteria
69. Purification and inhibition by quinolones of DNA gyrase from Mycobacterium avium, Mycobacterium smegmatis and Mycobacterium fortuitum bv, peregrinum
70. Homing events on the gyr A gene of some mycobacterial
71. Inteins in mycobacterial gyr A are a taxonomic character
72. Cloning and nucleotide sequence of M. tuberculosis gyr A and gyr B genes and detection of quinolone resistance mutations
73. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence
74. Fluoroquinolone action in mycobacteria: Similarity with effects in Escherichia coli and the detection by cell lysate viscosity
75. Gyrase mutations in laboratory-selected fluoroquinolone-resistant mutants of Mycobacterium tuberculous H37Ra
76. Rapid Mycobacterium species assignment and unambigous identification of mutations associated with antibiotic resistance in Mycobacterium tuberculosis by automated DNA sequencing
77. Selection of gyr A mutant of Mycobacterium tuberculosis resistant to fluoroquinolones during treatment with ofloxacin
78. Amplification and nucleotide sequence of the quinolone determining region in the gyr A gene of mycobacteria
79. Characterization of fluoroquinolone-resistant mutant strains of Mycobacterium tuberculosis selected in the laboratory and isolated from patients
80. Inhibitory activity of quinolones against DNA gyrase of Mycobacterium tuberculosis
81. Emergence during unsuccessful chemotherapy of multiple drug resistance in a strain of Mycobacterium tuberculosis
82. Efflux pump of the proton antiporter family confers low-level fluoroquinolone resistance in Mycobacterium smegmatis
83. Active efflux of fluoroquinolones in Mycobacterium segmatis mediated by LfrA, multidrug efflux pump
84. The structure and fonction of drugs pumps
85. Molecular cloning and characterization of Tap, a putative multidrug efflux pump present in Mycobacterium fortuitum and Mycobacterium tuberculosis
86. Involvement of an efflux system in mediating high level of fluoroquinolone resistance in Mycobacterium smegmatis
87. Mycobacterium tuberculosis invades and replicates within type II alveolar cells
88. Intracellular growth of pathogenic mycobacteria in the continous murine macrophage cell line J-774: Ultrastructure and drug susceptibility studies
89. Effectiveness of ofloxacin against Mycobacterium tuberculosis and Mycobacterium avium and rifampicin against M.tuberculosis in cultured human macrophages
90. An in vitro investigation of the bioactivities of a ciprofloxacin and the new fluoroquinolone agent clinafloxacin (CI-960) and PD 131,628 against Mycobacterium tuberculosis in human macrophages
91. Intracellular bactericidal activity of ciprofloxacin and ofloxacin against Mycobacterium tuberculosis H37Ra multiplying in the J-774 macrophage cell line
92. Cytotoxicity for lung epithelial cells is a virulence-associated phenotype of Mycobacterium tuberculosis
93. Antimicrobial activities of benzoxazino rifampicin (KRM-1648) and clarithromycin against Mycobacterium avium intracellulare complex residing in murine peritoneal macrophages, human macrophage-like cells cells
94. Antimicrobial activities of levofloxacin, clarithromycin and KRM-1648 against Mycobacterium tuberculosis and Mycobacterium avium complex replicating within mono Mac 6 human macrophage and A-549 type II alveolar cell line
95. Fluoroquinolone action against clinical isolates of Mycobacterium tuberculosis: Effects of a C-8 methoxy group on survival in liquid media in human macrophages
96. Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice
97. In vitro activity of ofloxacin against Mycobacterium tuberculosis
98. An update on the efficacy of ciprofloxacin in animal models of infection
99. Brief report: Combination chemotherapy with ciprofloxacin for infection with M. tuberculosis in a mouse model
100. Moxifloxacin (BAY 12-8039), a new 8-methoxy quinolone is active in a mouse model of tuberculosis
101. Which aminoglycoside or fluoroquinoilone is more active against Mycobacterium tuberculosis in mice?
102. Structure - Activity relationships of the quinolone antibacterials against mycobacteria: Effect of structural changes at N-1 and C-7
103. Effect of lipophilicity at N-1 on activity of fluoroquinolones against mycobacteria
104. Structure - Activity relationships of quinolone agents against mycobacteria: Effect of structural modifications at the 8 position
105. Fluoroquinolones resistance associated with specific gyrase mutations in clinical isolates of multi-drug resistant Mycobacterium tuberculosis
106. Fluoroquinolones action against mycobacteria: Effect of C-8 substituents growth, survival and resistance
107. Antituberculous activity of norfloxacin Mannich bases with isatin derivatives
108. Effect of fluoroquinolone concentration on selection of mutants of Mycobacterium bovis BCG and Staphylococcus aureus
109. Mutant prevention concentration as a measure of fluoroquinolone potency against mycobacteria
110. Influence of N-substitution on antimycobacterial activity of ciprofloxacin
111. Nitroquinolones with broad spectrum antimycobacterial activity in vitro
112. Novel anti-acid-fast-bacterial agents containing pyridonecarboxylic acids WO-00158876-
113. Ofloxacin in military tuberculosis
114. Ciprofloxacin in patients in the mycobacterial infections: Experience in 15 patients, DICP
115. Therapeutic effects of ofloxacin on intractable pulmonary tuberculosis and ofloxacin resistance of tubercle bacilli isolated from the patients
116. In vitro activity of ofloxacin against Mycobacterium tuberculosis and its clinical efficacy in multiply resistant pulmonary tuberculosis
117. Efficacy of low-dose ofloxacin in the treatment of multidrug-resistant tuberculosis in Indonesia
118. Ofloxacin-based chemotherapy in multiply drug-resistant pulmonary tuberculosis
119. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin - Containing regimens
120. Prospective comparative study of ofloxacin or ethambutol for the treatment of pulmonary tuberculosis
121. Safety profile of ciprofloxacin during long-term therapy for pulmonary tuberculosis
122. Early bactericidal and sterilizing activities of ciprofloxacin in pulmonary tuberculosis
123. Controlled trial of ciprofloxacin short-term chemotherapy for pulmonary tuberculosis
124. Randomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of tuberculosis
125. The early bactericidal of ciprofloxacin in patients with pulmonary tuberculosis
126. Early bactericidal activity and sterilizing activity of ciprofloxacin in pulmonary tuberculosis
127. The early bactericidal activity of drugs in patients with pulmonary tuberculosis
128. Ciprofloxacin once-daily versus twice daily for the treatment of pulmonary tuberculosis
129. Levofloxacin for drug resistant Mycobacterium tuberculosis
130. Novel treatment of meningitis caused by multidrug resistant Mycobacterium tuberculosis with intrathecal levofloxacin and amikacin: Case report
131. Treatment of tuberculosis in HIV infection
132. Early experience with sparfloxacin in tuberculosis
133. Ambulatory regimen with sparfloxacin and combined old antituberculosis drugs plus synergy for treatment of multidrug resistant tuberculosis
134. Use of sparfloxacin for the treatment of multidrug resistant pulmonary tuberculosis
135. Sparfloxacin in the treatment of drug resistant tuberculosis or intolerance of first line therapy
136. Use of Maxaquin® in the treatment of progressive pulmonary tuberculosis occuring with standard chemotherapy regimens
137. Lomefloxacin in complex treatment of acute progressive form of pulmonary tuberculosis
138. Maxaquin® in the combined treatment of tuberculosis
139. Mechanism of action of lomefloxacin on Mycobacterium tuberculosis
140. An uncontrolled trial of pefloxacin in the retreatment of patients with pulmonary tuberculosis
141. Resistant tuberculosis: Successful treatment with amikacin, ofloxacin, clofazimine and PAS
142. Traitement de sauvetage d'une tuberculose pulmonaire multiréistante. Efficacité de la péfloxacine
143. A controlled study of a ribafutin and an uncontrolled study of ofloxacin in the retreatment of patients with pulmonary tuberculosis resistant to isoniazid, streptomycin and rifampicin
144. Ofloxacin in the retreatment of patients with pulmonary tuberculosis resistance to isoniazid, streptomycin and rifampicin, a South Indian experience
145. Tuberculomes intracrâniens multiples. Aspect en imagerie par résonance magnétique nucléaire et apport thérapeutique de l'ofloxacine
146. Dynamic computed tomography of cerebral parenchymal tuberculomata
147. Intracranial tuberculoma: Case report and review of the literature
148. Tuberculose péritonéale décapitée par les fluoroquinolones chez un malade atteint de cirrhose
149. Efficacité transitoire de la péfloxacine au cours d'une ostéoarthrite tuberculeuse
150. Ciprofloxacin treatment of multiply drug-resistant extrapulomnary tuberculosis in a child
151. Comparative in vitro activities of ciprofloxacin and other 4-quinolones agents against Mycobacterium tuberculosis and Mycobacterium intracellulare
152. Chemoprophylaxis of multidrug-resistant tuberculosis infections in HIV-uninfected individual using ciprofloxacin and pyrazinamide: A decision analysis
153. Treatment of tuberculosis and tuberculosis infection in adults and children
154. Asymptomatic hepatitis in persons who received alternative preventive therapy with pyrazinamide and ofloxacin
155. Limited tolerance of ofloxacin and pyrazinamide prophylaxis against tuberculosis
156. The role of fluoroquinolones in tuberculosis today
157. Ciprofloxacin is not a component of first-line TB
158. Controlled trial of ciprofloxacin in short-term chemotherapy for pulmonary tuberculosis
159. Ciprofloxacin in the management of pulmonary tuberculosis in the face of hepatic dysfunction
160. Tolerance of ofloxacin in the treatment of pulmonary tuberculosis in presence of hepatic dysfunction
161. Long-term treatment of pulmonary tuberculosis with ofloxacin in a subject with liver cirrhosis
162. Guidelines for the management of drug-resistant tuberculosis
163. Epidemiology control and treatment of multidrug resistant tuberculosis
164. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis
165. A case of resistant tuberculosis
166. Quinolone-induced arthropaty in the neonatal mouse. Morphological analysis of articular lesions produced by pipemidic acid and ciprofloxacin
167. Wordwide clinical experience on safety of ciprofloxacin in children on compassionate use basis
168. Drug treatment for tuberculosis during pregnancy - Safety considerations
169. Pregnancy outcome following gestional exposure to fluoroquinolones: A multicenter, prospective, controlled study
170. Adverse neurological reactions in patients with multidrug-resistant pulmonary tuberculosis after non administration of cycloserine and ofloxacin
171. Long-term safety of ofloxacin and ciprofloxacin in the treatment of mycobacterial infection
172. Malabsorption of antituberculous medications by patients with AIDS
173. Mycobacteria and the new quinolones
174. Differentiation of Mycobacterium gordonae from Mycobacterium scorfulaceum and Mycobacterium szulgai by susceptibility to enoxacin (antimycobacterial activity of enoxacin)
175. Differentiation between mycobacterial species by the susceptibility test to ciprofloxacin. Comparison of antimycobacterial spectrum between ofloxacin and ciprofloxacin
176. Fluoroquinolones: A new treatment for tuberculosis
177. The clinical use of fluoroquinolones for the treatment of mycobacterial diseases
178. Minimal inhibitory concentrations of rifabutin, ciprofloxacin, and ofloxacin against Mycobacterium tuberculosis isolates before treatment of patients in Taiwan